9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
10 citations
,
June 2024 in “American Journal of Clinical Dermatology” Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.
16 citations
,
March 2013 in “JAMA Dermatology” A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
1 citations
,
September 2024 in “Frontiers in Pharmacology” Aumolertinib effectively controls lung cancer and improves quality of life.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
14 citations
,
August 2021 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
November 2025 in “Journal of Investigative Dermatology”
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
January 2025 in “Journal of the American Academy of Dermatology” Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.
9 citations
,
December 2014 in “British Journal of Dermatology” Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
August 2024 in “Asian Journal of Research in Chemistry” Repurposing existing drugs can improve cancer treatment but faces challenges.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.